Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Seres Therapeutics (MCRB) Reports In-Line Q1 EPS, Revenues Miss
May 7, 2020 7:57 AM EDTSeres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.28), in-line with the analyst estimate of ($0.28). Revenue for the quarter came in at $8.19 million versus the consensus estimate of $8.53 million.
We were pleased to have recently achieved the important milestone of completing enrollment of our... More
